Summary
75 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 22% a year over the last 3 years.
- It earns 30 ZAR a year on every 100 ZAR of invested capital.
- You pay 17.1 ZAR for 1 ZAR of yearly profit, little for its sector.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.1 ZAR for 1 ZAR of yearly profit. Over the last five years it was 31.1 ZAR on average.
Valuation in detailIs it growing?
Yes, fastRevenue (ZAR)
Diluted EPS (ZAR)
- Analyst estimate
Revenue grew by 7.8% a year over 5 years. Over the last 3 years it grew by 8.1% a year. Earnings per share grew by 22% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 ZAR of revenue goes
- Cost of sales 73 ZAR
- Sales and administration 16 ZAR
- Taxes and other 2.8 ZAR
- Net profit 6.1 ZAR
Net profit, industry median (Medical - Pharmaceuticals) 4.8 ZAR
Out of every 100 ZAR of revenue, 6.1 ZAR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 4.02%
- Paid out of profit
- 69%
- Raised in a row
- 3 years
You receive $1.13 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 1
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.